Navigation Links
Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
Date:6/24/2009

er the years, St. Jude investigators have identified many important risk factors for CNS relapse and optimized chemotherapy treatment, leading to improved control of CNS relapse," Pui said. "Our success led us to believe that we could safely eliminate the use of cranial irradiation in all patients, and this study clearly demonstrates that to be true."

The study involved 498 patients treated for ALL at St. Jude and Cook Children's Medical Center in Fort Worth, Texas, between 2000 and 2007. The risk of relapse was determined by measurement of residual leukemia cells (so-called minimal residual disease) that were present after remission induction treatment. The measurement of minimal residual disease was used to modify therapy based on the level of disease detected. This measurement is the most important prognostic indicator, according to Dario Campana, M.D., Ph.D., vice chair for laboratory research in the St. Jude Department of Oncology and a co-author of the paper. "The combined use of immunological and molecular methods allows us to study 100 percent of the patients for levels of minimal residual disease, an unprecedented rate of success," Campana said.

St. Jude investigators applied personalized therapy based on molecular genetics of ALL, pharmacogenetic traits of patients and pharmacodynamic principles. "We prospectively determined the activity of drug-metabolizing enzymes of each patient and adjusted the dosage of chemotherapy accordingly," said Mary Relling, Pharm.D., chair of the St. Jude Department of Pharmaceutical Sciences and senior author of the paper. "Personalized therapy that we use avoids over- or under-treatment to maximize the cure rate while preventing excessive toxicity."

The researchers reported that this therapy produced a projected cure rate of 90 percent for all the patients, which is the best treatment result reported to date. This cure rate serves as a benchmark for others in the field. To
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... , SALT LAKE CITY, Nov. 27 /PRNewswire-Firs...al Systems, Inc. (NYSE: VAR ), a premier supplie...ctors, will exhibit its full range of detectors at...ember 29 - December 3, 2009. Varian will also be ...lities as well as specialized cancer treatment tec...
(Date:11/26/2009)... , JOHANNESBURG, South Africa, Nov. 26 /PR...frica Company of the Year Award in the Generic Pha...uth Africa Limited. ,, (Logo: http://www.newsc...e Company of the Year Award, the following criteri...e against key competitors: growth strategy and imp...
(Date:11/25/2009)... , LOVELAND, Colo., Nov. 25 /PRNewswire-Fir... leading provider of advanced diagnostic and spe...ced today agreements with Roche Diagnostics Corpor...iliated consumables for the veterinary market. .../20000622/HESKALOGO ) ,, "Heska and Roche share...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Texas Doctor Files Case Pro Se in U S Supreme Court Against Insurance Giant on Integrity and Unethical Practices 58242 1Texas Doctor Files Case Pro Se in U S Supreme Court Against Insurance Giant on Integrity and Unethical Practices 58242 2Texas Doctor Files Case Pro Se in U S Supreme Court Against Insurance Giant on Integrity and Unethical Practices 58242 3New Cardiovascular Biomarker Available for Scientist in North America 5054 1New Cardiovascular Biomarker Available for Scientist in North America 5054 230th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 130th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 230th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 330th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 4
...Achieves Primary Endpoint Among High-Risk Infants ...n of Medically Attended,Outpatient RSV- Related Lo...7 /PRNewswire-FirstCall/ -- MedImmune, Inc.,today ...e trial,conducted for prevention of respiratory sy...b, the investigational monoclonal antibody,(MAb) a...
...D--(BUSINESS WIRE)--May 10, 2007 - An evaluation o...trogen therapy for the,treatment of vaginal atroph...as just been released by The North American,Menopa...ginal,estrogen for treatment of vaginal atrophy in...The North American Menopause Society,",the documen...
Other Medicine Technology:MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 2New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 3
(Date:11/28/2009)...eved to affect circadian rhythm, , ,... suggests that an internal body clock that goes on... bipolar disorder in children. , The finding r...of 152 children with bipolar disorder, which can m...40 children without the disorder. They linked vari...
(Date:11/27/2009)...v. 27 GSI Group Inc. (Pi...ecision technology products and semiconductor syst... Company,s shareholders has been scheduled for Fri... meeting will be announced in due course. As prev...on notice from Stephen Bershad, a holder of greate...
(Date:11/27/2009)...ch firm Replikins Ltd. today issued its latest bio... It shows that the lethality of the virus has drop...us,s current outbreak in the spring of 2009 to res...1). The H1N1 infectivity count, however, remains i...) November 27, 2009 -- Biotech firm Replikins Ltd....
(Date:11/27/2009)...27 The Gymboree Corporat... CFO/COO, will present at the NASDAQ OMX 23rd Inve...otel in London, England, on Wednesday, December 2,...e broadcast of The Gymboree Corporation,s presenta...ree.com, click on "Our Company" at the bottom of t...
(Date:11/27/2009)..., France, Nov. 27 Team Garmin-Slip...am dedicated to ethical sporting and developing th...today that it will become Team Garmin-Transitions ...sponsor of the team. Transitions Optical is the wo...fering the most advanced photochromic technology i...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...t to interferon beta treatments , WEDNESDAY, Jan. ...xplain why some multiple sclerosis (MS) patients r...n international study. , Starting with 206 souther... reduced by interferon beta therapy to the DNA of ...
... Center New Orleans has been selected as the inaug...William J. Gies Award for Outstanding Innovation. ...tion at a black-tie celebration on March 29, 2008 .... Gies, a pioneer in dental education, the William...
...ements in key genes connected to the p53 regulator...y creating additional safeguards in human genes to...amage that could cause cancer or a variety of gene...l Academy of Sciences. Because genetically engine...
...hicago are still being exposed to chemicals banned.... The chemicals do not appear to be affecting the ...gs appear in the current issue of the Journal of G...e Illinois Natural History Survey, said that chemi...
... by Reverend Carlton W. Veazey, President and CEO ...:, "On the 35th anniversary of Roe v. Wade, our c...t that abortion will be safe, legal, and available...g promoted in at least 17 states are sounding the ...
...l Costs, WILMINGTON, Del., Jan. 16 Bollig & Kemp...pean auto industry, has signed,a license agreement...logy,that enables auto manufacturers to realize su...acture and sell water-based basecoats for use in t...
Other Medicine News:Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:LSUHSC dental school to be awarded top national honor 2Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 2Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 3Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 4Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 3Health News:Statement of the Reverend Carlton W. Veazey, President and CEO of the Religious Coalition for Reproductive Choice, on the 35th Anniversary of Roe v. Wade 2Health News:DuPont Licenses Breakthrough Automotive Coating Technology to German Paint Maker 2
Malis Needle Holders
Vascular Clamps RD-S
Vascular Clamps B-1
Micro Emulsifying Needles
Medicine Products: